Viking Therapeutics, Inc. (VKTX)
NASDAQ: VKTX · Real-Time Price · USD
32.01
-0.06 (-0.19%)
At close: Jul 18, 2025, 4:00 PM
32.20
+0.19 (0.59%)
After-hours: Jul 18, 2025, 7:59 PM EDT
Viking Therapeutics Stock Forecast
Stock Price Forecast
The 12 analysts that cover Viking Therapeutics stock have a consensus rating of "Buy" and an average price target of $84, which forecasts a 162.42% increase in the stock price over the next year. The lowest target is $30 and the highest is $138.
Price Target: $84 (+162.42%)
Analyst Consensus: Buy
Analyst Ratings
The average analyst rating for Viking Therapeutics stock is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
Rating | Feb '25 | Mar '25 | Apr '25 | May '25 | Jun '25 | Jul '25 |
---|---|---|---|---|---|---|
Strong Buy | 8 | 6 | 4 | 4 | 4 | 4 |
Buy | 5 | 5 | 6 | 6 | 6 | 6 |
Hold | 1 | 1 | 2 | 2 | 2 | 2 |
Sell | 0 | 0 | 0 | 0 | 0 | 0 |
Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
Total | 14 | 12 | 12 | 12 | 12 | 12 |
Latest Forecasts
Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
---|---|---|---|---|---|---|---|
HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $102 | Strong Buy | Reiterates | $102 | +218.65% | Jun 25, 2025 |
Cantor Fitzgerald | Cantor Fitzgerald | Buy Initiates $104 | Buy | Initiates | $104 | +224.90% | Apr 28, 2025 |
Truist Securities | Truist Securities | Strong Buy Reiterates $95 → $75 | Strong Buy | Reiterates | $95 → $75 | +134.30% | Apr 28, 2025 |
Morgan Stanley | Morgan Stanley | Buy Maintains $105 → $102 | Buy | Maintains | $105 → $102 | +218.65% | Apr 24, 2025 |
HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $102 | Strong Buy | Reiterates | $102 | +218.65% | Apr 24, 2025 |
Financial Forecast
Revenue This Year
n/a
from 706.68M
Revenue Next Year
n/a
EPS This Year
-1.93
from -1.01
EPS Next Year
-2.62
from -1.93
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
---|---|---|---|---|---|
High | 26.3M | 97.9M | 292.9M | ||
Avg | 1.5M | 6.6M | 28.2M | ||
Low | n/a | n/a | n/a |
Revenue Growth
Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
---|---|---|---|---|---|
High | -96.3% | 6,424.0% | 4,351.3% | ||
Avg | -99.8% | 338.6% | 328.9% | ||
Low | - | - | - |
EPS Forecast
EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
---|---|---|---|---|---|
High | -1.55 | -1.86 | -1.80 | ||
Avg | -1.93 | -2.62 | -3.04 | ||
Low | -2.52 | -3.93 | -4.19 |
EPS Growth
EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
---|---|---|---|---|---|
High | - | - | - | ||
Avg | - | - | - | ||
Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.